Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.
作者： Jayasankar Kosaraju , Chaitanya Chakravarthi Gali , Rizwan Basha Khatwal , Anil Dubala , Santhivardhan Chinni
DOI: 10.1016/J.NEUROPHARM.2013.04.008
关键词:
摘要: Type 2 diabetes (T2D) is one of the major risk factors associated with Alzheimer's disease (AD). Recent studies have found similarities in molecular mechanisms that underlie respective degenerative developments two diseases. Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase level glucagon-like peptide-1 (GLP-1) and ameliorate T2D, become valuable candidates modifying agents treatment AD. In addition, endogenous GLP-1 levels decrease amyloid beta (Aβ) peptide tau phosphorylation The present study examines efficacy Saxagliptin, a DPP-4 inhibitor streptozotocin (STZ) induced rat model Three months following induction AD by intracerebral administration streptozotocin, animals were orally administered Saxagliptin (0.25, 0.5 1 mg/kg) for 60 days. effect on hippocampal levels, Aβ burden, phosphorylation, inflammatory markers memory retention evaluated. results reveal an attenuation Aβ, improvement treatment. This remarkable therapeutic mediated through inhibition demonstrates unique mechanism clearance increasing reverses behavioural deficits pathology observed
elsevier.com
sci-hub.se 参考文章(55)
Kenneth S. Kosik, Lisa D. Orecchio, Shelley Bakalis, Rachael L. Neve, Developmentally regulated expression of specific tau sequences. Neuron. ,vol. 2, pp. 1389- 1397 ,(1989) , 10.1016/0896-6273(89)90077-9
DENNIS W. DICKSON, The pathogenesis of senile plaques Journal of Neuropathology and Experimental Neurology. ,vol. 56, pp. 321- 339 ,(1997) , 10.1097/00005072-199704000-00001
Michelle T. Fodero-Tavoletti, Victor L. Villemagne, Christopher C. Rowe, Colin L. Masters, Kevin J. Barnham, Roberto Cappai, Amyloid-β: The seeds of darkness The International Journal of Biochemistry & Cell Biology. ,vol. 43, pp. 1247- 1251 ,(2011) , 10.1016/J.BIOCEL.2011.05.001
P. L. McClean, V. Parthsarathy, E. Faivre, C. Holscher, The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease The Journal of Neuroscience. ,vol. 31, pp. 6587- 6594 ,(2011) , 10.1523/JNEUROSCI.0529-11.2011
George G. Glenner, Caine W. Wong, Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochemical and Biophysical Research Communications. ,vol. 120, pp. 885- 890 ,(1984) , 10.1016/S0006-291X(84)80190-4
Michele d’Amico, Clara Di Filippo, Raffaele Marfella, Angela Maria Abbatecola, Franca Ferraraccio, Francesco Rossi, Giuseppe Paolisso, Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Experimental Gerontology. ,vol. 45, pp. 202- 207 ,(2010) , 10.1016/J.EXGER.2009.12.004
Christian Holscher, Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Patents on Cns Drug Discovery. ,vol. 5, pp. 109- 117 ,(2010) , 10.2174/157488910791213130
C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome Proceedings of the National Academy of Sciences of the United States of America. ,vol. 82, pp. 4245- 4249 ,(1985) , 10.1073/PNAS.82.12.4245
Jaime Grutzendler, John C. Morris, Cholinesterase inhibitors for Alzheimer's disease. Drugs. ,vol. 61, pp. 41- 52 ,(2001) , 10.2165/00003495-200161010-00005
Ok Kyu Park, Jung Hoon Choi, Joon Ha Park, In Hye Kim, Bing Chun Yan, Ji Hyeon Ahn, Seung-Hae Kwon, Jae-Chul Lee, Young Sup Kim, Misook Kim, Il-Jun Kang, Jong-Dai Kim, Yun Lyul Lee, Moo-Ho Won, Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage Fitoterapia. ,vol. 83, pp. 1666- 1674 ,(2012) , 10.1016/J.FITOTE.2012.09.020